Ontology highlight
ABSTRACT:
SUBMITTER: Arguelles-Arias F
PROVIDER: S-EPMC5487700 | biostudies-other | 2017 May
REPOSITORIES: biostudies-other
Argüelles-Arias F F Guerra Veloz M F MF Perea Amarillo R R Vilches-Arenas A A Castro Laria L L Maldonado Pérez B B Chaaro D D Benítez Roldán A A Merino V V Ramírez G G Caunedo Álvarez A A Romero Gómez M M
Digestive diseases and sciences 20170309 5
<h4>Background</h4>CT-P13 is a biosimilar of Remicade<sup>®</sup>, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD.<h4>Aims</h4>To assess the effectiveness and safety of CT-P13 in IBD patients in real clinical practice.<h4>Methods</h4>This is a prospective observational study in patients with moderate to severe Crohn's disease or ulcerative colitis ...[more]